Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65293 | 0.91 | CYP19A1 (0.62) | SMN1; SMN2CYP3A4NPC1CYP19A1ALDH1A1 | |
| Acrylamide SCHEMBL27801304 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP3A4NPC1CYP19A1ALDH1A1 | |
| SCHEMBL539064 | 0.85 | ALDH1A1 (0.60) | SMN1; SMN2CYP3A4NPC1CYP19A1ALDH1A1 | |
| SCHEMBL5538329 | 0.85 | CYP19A1 (0.62) | SMN1; SMN2CYP3A4CYP19A1ALDH1A1LMNA | |
| SCHEMBL1172383 | 0.84 | SMN1; SMN2 (0.78) | SMN1; SMN2CYP3A4NPC1ALDH1A1LMNA | |
| SCHEMBL3913976 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2CYP3A4NPC1CYP19A1ALDH1A1 | |
| SCHEMBL1718796 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2CYP3A4NPC1CYP19A1ALDH1A1 | |
| SCHEMBL91307 | 0.79 | NPC1 (0.59) | SMN1; SMN2CYP3A4NPC1ALDH1A1LMNA | |
| SCHEMBL18983905 | 0.79 | NPC1 (0.59) | SMN1; SMN2CYP3A4NPC1ALDH1A1LMNA | |
| SCHEMBL7083340 | 0.78 | NPC1 (0.62) | SMN1; SMN2CYP3A4NPC1CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794621-B1 | NOVEL ORGANOSILICA COMPOUNDS | UNIV GENT (BE) | 2018-09-26 | — | — | EP | disclosed |
| US-9181282-B2 | Organosilica compounds | UNIVERSITEIT GENT (BE) | 2015-11-10 | — | — | US | disclosed |
| US-20150005525-A1 | NOVEL ORAGNOSILICA COMPOUNDS | UNIVERSITEIT GENT (BE) | 2015-01-01 | — | — | US | disclosed |
| EP-2794621-A1 | NOVEL ORGANOSILICA COMPOUNDS | Universiteit Gent (BE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093022-A1 | NOVEL ORGANOSILICA COMPOUNDS | UNIVERSITEIT GENT (BE) | 2013-06-27 | — | — | WO | disclosed |
| US-20100032547-A1 | METHOD AND SYSTEM OF ARRAY IMAGING | TUFTS UNIVERSITY (US) | 2010-02-11 | — | — | US | disclosed |
| EP-1960748-A2 | METHOD AND SYSTEM OF ARRAY IMAGING | Tufts University (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008051189-A2 | METHOD AND SYSTEM OF ARRAY IMAGING | TUFTS UNIVERSITY (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005525-A1 | NOVEL ORAGNOSILICA COMPOUNDS | ORC3, ORMDL3, OR10J3 | SMN1; SMN2 4780/4885CYP3A4 1310/4885NPC1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.